Funding and Grants

Current Funding Opportunities

MCW Cancer Center Pilot Funding ProgramWinter 2017 Special RFA, American Cancer Society Pilot Grants 

 

► MCW Cancer Center Pilot Funding Award Cycles

 

 

 

Spring 2016

Fall 2017

RFA Released

5/15/2016

11/15/2016 Click Here for RFA and Forms

LOI Due

6/1/2016

12/1/2016

Application Due

7/15/2016

1/15/2017

Review Committees

8/21 - 9/4/2016

2/13 – 2/25/2017

Funding Decision

First Thursday of  October

First Thursday of April

Earliest Start Date

1/1/2017

6/1/201

 

Spring 2017

Fall 2018

RFA Released

5/15/2017

11/15/2017

LOI Due

6/12017

12/1/2017

Application Due

7/14/2017

1/15/2018

Review Committees

8/21 - 9/1/2017

2/15 – 2/26/2018

Funding Decision

First Thursday of October

First Thursday of April

Earliest Start Date

1/1/2018

6/1/2018

 

National Cancer Institute (NCI)

Open AllClose All
  Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33) (Deadline: 2/28/17)

Advanced Development and Validation of Emerging Biospecimen Science Technologies for Basic and Clinical Cancer Research (R33)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33) (Deadline: 2/28/17)

Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on further development and validation of emerging technologies offering novel capabilities for targeting, probing, or assessing molecular and cellular features of cancer biology for basic or clinical cancer research. This FOA solicits R33 applications where major feasibility gaps for the technology or methodology have been overcome, as demonstrated with supportive preliminary data, but still requires further development and rigorous validation to encourage adoption by the research community. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer. Projects proposing application of existing technologies where the novelty resides in the biological or clinical target/question being pursued are not appropriate for this solicitation and will not be reviewed.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21) (Deadline: 2/28/17)

Innovative Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R21)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies offering novel molecular or cellular analysis capabilities for basic or clinical cancer research. The emphasis of this FOA is on supporting the development of novel capabilities involving a high degree of technical innovation for targeting, probing, or assessing molecular and cellular features of cancer biology. Well-suited applications must offer the potential to accelerate and/or enhance research in the areas of cancer biology, early detection and screening, clinical diagnosis, treatment, control, epidemiology, and/or address issues associated with cancer health disparities. Technologies proposed for development may be intended to have widespread applicability but must be focused on improving molecular and/or cellular characterizations of cancer biology.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  Innovative Technologies for Cancer-Relevant Biospecimen Science (R21) (Deadline: 2/28/17)

Innovative Technologies for Cancer-Relevant Biospecimen Science (R21)

This Funding Opportunity Announcement (FOA) solicits grant applications proposing exploratory research projects focused on the early-stage development of highly innovative technologies that improve the quality of the samples used for cancer research or clinical care. This includes new capabilities to address issues related to pre-analytical degradation of targeted analytes during the collection, processing, handling, and/or storage of cancer-relevant biospecimens. The overall goal is to support the development of highly innovative technologies capable of maximizing or otherwise interrogating the quality and utility of biological samples used for downstream analyses. This FOA will support the development of tools, devices, instrumentation, and associated methods to preserve or protect sample integrity, or establish verification criteria for quality assessment/quality control and handling under diverse conditions. These technologies are expected to accelerate and/or enhance research in cancer biology, early detection and screening, clinical diagnosis, treatment, epidemiology, or address issues associated with cancer health disparities, by reducing pre-analytical variations that affect biospecimen sample quality.

This funding opportunity is part of a broader NCI-sponsored Innovative Molecular Analysis Technologies (IMAT) Program.

Applications due February 28, 2017

  NCI Small Grants Program for Cancer Research (NCI Omnibus R03) (Deadline: 2/28/17)

NCI Small Grants Program for Cancer Research (NCI Omnibus R03)

This funding opportunity announcement (FOA) supports small research projects on cancer that can be carried out in a short period of time with limited resources. The R03 grant mechanism supports different types of projects including pilot and feasibility studies; secondary analysis of existing data; small, self-contained research projects; development of research methodology; and development of new research technology.

Applications due February 28, 2017

  Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01) (Deadline: 2/28/17)

Revision Applications for Validation of Biomarker Assays Developed Through NIH-Supported Research Grants (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to accelerate the pace of translation of NCI-supported methods/assays/technologies (referred to as "assays") to the clinic. Specifically, the focus of this FOA is on the adaption and clinical validation of molecular/cellular/imaging markers (referred to as "markers" or "biomarkers") for cancer detection, diagnosis, prognosis, monitoring, and prediction of response to treatment, as well as markers for cancer control and prevention. Research applications may support acquisition of well-annotated specimens from NCI-supported or other clinical trials or observational cohorts/consortia for the purpose of clinical validation of the assay. Research projects proposed for this FOA encourage multi-disciplinary interaction among scientific investigators, assay developers, clinicians, statisticians and clinical laboratory staff. Clinical laboratory scientist(s) and statistical experts are highly encouraged to comprise integral parts of the application.

This FOA is not intended to support early stage development of technology or the conduct of clinical trials, but rather the adaption and validation of assays to the point where they could be integrated into clinical trials as investigational assays/tools/devices.

Applications due February 28, 2017

  START Mentored Translational Research Training Program (Extended deadline: 2/28/17)

START Mentored Translational Research Training Program

The overall goal of the START TL1 Program award is to increase the number of well-trained clinician-scientists who can lead the design and oversight of future clinical investigations critical to transforming the translational process so that new treatments and cures for disease can be delivered to patients faster. The deadline to submit a Letter of Intent has been extended to Dec. 21, and the application deadline has been extended to Feb. 28.

For this award cycle, applications are being accepted for:

  • Pre-doctoral awardees (MD/PhD, PhD, MD/MS) conducting clinical and translational research
  • Postdoctoral awardees (DMD, DC, DO, DVM, OD, DPM, ScD, EngD, AuD, DPT, DPH, DNSc, PharmD, ND (Doctor of Naturopathy), DSW, PsyD, a doctoral degree in nursing research or practice or an MD obtaining additional Masters training) conducting clinical and translational research

All TL1 awardees receive:

  • Stipend support awarded at the NIH allowed annual maximum:  For Pre-Doctoral Scholars (PhDs, MD/MSs, MD/PhDs) is 80% protected time with a stipend of $23,376 for one year.  For Post-Doctoral Scholars (MD Fellows) is 80% protected time with a one-year stipend, dollar amount varying depending on years of experience
  • Up to $5,700 for Pre-Doctoral Scholars and for Post-Doctoral Scholars up to $10,350 to defray the cost of the research program (including fringe benefits and travel to national meetings)
  • Access to the CTSI professional services and staff including biostatistics, subject recruitment, and human subjects approval; and access to a training curriculum in clinical and translational research methodology and specialized training seminars.
  • Up to 60% of tuition may be reimbursed

Applications due February 28, 2017

  Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01) (Deadline: 3/1/17)

Academic-Industrial Partnerships to Translate and Validate in vivo Cancer Imaging Systems (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate translation of scientific discoveries and engineering developments in imaging or spectroscopic technologies into methods or tools that address problems in cancer biology, risk of cancer development, diagnosis, treatment, and/or disease status.

A distinguishing feature of each application will be formation of an academic-industrial partnership, which is a strategic alliance of investigators in academic, industrial, and any other entities who work together as partners to identify and translate a technological solution or mitigation of a cancer-related problem.

The goals for proposed technologies are imaging applications in clinical trials, clinical research, non-clinical research, and/or patient care. Among other possibilities, they may include pre-clinical imaging investigations or investigations that combine patient specimens and pre-clinical methods, or optimizations of methods across different commercial platforms, sites, or time.

Applications due March 1, 2017

  Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp) (Deadline: 3/1/17)

Administrative Supplements for Research on Sexual and Gender Minority (SGM) Populations (Admin Supp)

The NIH Office of the Director announces the availability of administrative supplements to expand existing research to focus on Sexual and Gender Minority (SGM) health. SGM populations include, but are not limited to, lesbian, gay, bisexual, and transgender people, and individuals with differences or disorders of sexual development (sometimes referred to as “intersex” or as specific diagnoses). This trans-NIH effort, which involves multiple Institutes, Centers and Offices from across NIH, is intended to encourage investigation in this underrepresented, but growing, field of research. To increase our collective understanding of the broad range of the health needs of SGM populations, the supplement will focus on areas of specific research interest, including, but not limited to: studies on increased disease risk; mental, behavioral and social health; approaches to personalized medicine; access to care; reproductive and sexual development; neurological and cognitive development; and resilience.

Applications due March 1, 2017

  Cancer Immunologic Data Commons (CIDC) (U24) (Deadline: 3/3/17)

Cancer Immunologic Data Commons (CIDC) (U24)

The purpose of this funding opportunity announcement (FOA) is to solicit applications for establishment of a Cancer Immunologic Data Commons (CIDC) to provide bioinformatics support as part of a Network for correlative studies in clinical trials involving cancer immunotherapy. The Network will encompass a single CIDC award (to be supported by this FOA) and up to three Cancer Immune Monitoring and Analysis Centers (CIMACs) (to be supported by a companion FOA, RFA-CA-17-005).

The goal of the CIMACs-CIDC Network is to enable systematic incorporation of biomarker studies in NCI-supported early clinical trials for immunotherapy. CIMACs will be responsible for comprehensive analyses of biospecimens from patients for biomarkers relevant to genomic, phenotypic, and functional aspects of responses to immunotherapy. CIDC will serve the bioinformatics needs of the Network, including collection, integration, access, and analysis of data generated from CIMACs. The CIDC will also contribute to the long-term goal of creating publically accessible Data Commons for cancer immune profiling as well as clinical data that will allow integrated analysis across trials and access by the larger immuno-oncology research community.

Specifically, the CIDC will be expected to:

  • Adopt or develop data collection standards and database modules for key assay platforms for tumor- and immune-profiling. This will be done in collaboration with CIMACs.
  • Establish database for collection and management of biomarker and associated clinical data generated from CIMACs.
  • Provide and maintain bioinformatics tools for data access and multi-dimensional analysis within and across trials in the CIMACs.
  • Facilitate regulated data sharing and access by outside investigators and research community, as appropriate and consistent with achieving the goals of the program.

The long term goal of the CIMACs-CIDC Network is to develop molecular signatures that define immune response categories to correlate with the clinical outcomes of immunotherapy in cancer. Collectively, the outcome of the Network research should lead to the identification of biomarkers with a translational potential for optimizing the therapeutic strategies for patients.

Applications are due March 3, 2017

  Cancer Immunologic Data Commons (CIDC) (U24) (Deadline: 3/3/17)

Cancer Immunologic Data Commons (CIDC) (U24)

This National Cancer Institute (NCI) funding opportunity announcement (FOA) solicits applications for multidisciplinary Cancer Immune Monitoring and Analysis Centers (CIMACs) that will serve as the main units of the Network for correlative studies in clinical trials involving immunotherapy. The Network will encompass two to three CIMACs (to be supported by this FOA) and a single Cancer Immunologic Data Commons (CIDC) (to be supported by the companion FOA, RFA-CA-17-006) forming a CIMACs-CIDC Network.

The Network is established to address the critical importance of biomarkers in management of cancer patients receiving immunotherapy. Specifically, each CIMAC will encompass a multidisciplinary group with basic, translational, clinical, and computational research expertise. CIMACs are expected to provide a wide range of state-of-the-art analyses for genomic, phenotypic and functional characterization of responses of patients in the NCI-sponsored early phase clinical trials using analytically-validated and standardized platforms. The Network activities will be facilitated by the CIDC in the following main areas: optimization of data collection methodologies suitable for immune-related biomarkers, data integration and building a biomarker database for the secondary use by the large immuno-oncology community.

The long term goal of the CIMACs-CIDC Network is to develop molecular signatures that define immune response categories to correlate with the clinical outcomes of immunotherapy in cancer. Collectively, the outcome of the Network research should lead to the identification of biomarkers with a translational potential for optimizing the therapeutic strategies for patients.

Applications due March 3, 2017

  Mechanisms of Cancer Drug Resistance and Sensitivity (U54) (Deadline: 3/3/17)

Mechanisms of Cancer Drug Resistance and Sensitivity (U54)

The goal of this Funding Opportunity Announcement (FOA) is to create a network of Drug Resistance and Sensitivity Centers (DRSCs) to develop innovative strategies to study mechanisms of tumor resistance or sensitivity to anticancer therapy. It is hoped that such studies will permit future efforts to identify and exploit these phenomena in clinical settings.

Each funded DRSC will become a member of the Drug Resistance and Sensitivity Network. Each DRSC may include multiple members and capabilities at the same or different institution that are necessary to fulfill the need for highly specialized multidisciplinary expertise. There may be multiple linked projects within each DSRC that will be under the overall authority of a Program Director/Principal Investigator (PD/PI). Applications involving several investigators from single or multiple institutions working together on a promising area of cancer resistance or sensitivity to drug therapy are encouraged.

The outputs from the DRSCs are expected to inform the development of novel strategies for precision medicine clinical trials (beyond the scope of this FOA) that can overcome drug resistance and sensitivity to anti-cancer agents.

Applications due March 3, 2017

  PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24) (Deadline: 3/3/17)

PDX Data Commons and Coordinating Center (PDCCC) for the PDX Development and Trial Centers Research Network (PDXNet) (U24)

The purpose of this funding opportunity announcement (FOA) is to establish a PDXNet Data Commons and Coordinating Center (PDCCC). PDCCC will interact with and coordinate with the PDX (Patient-Derived Xenograft) Development and Trial Centers Research Network (PDXNet) comprised of four PDX Development and Trial Centers (PDTCs, to be supported by companion FOA, RFA-CA-17-003) in a collaborative network.

The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine. The goals for PDTCs include: development of new PDX models and methods for preclinical testing of single agents and drug combinations; and using the newly established models as well as other existing well-characterized PDX models for studies of drug responses. The PDCCC will serve as the coordinating and data analysis center of the PDXNet. It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI's Experimental Therapeutic Clinical Trials Network (ETCTN).

PDXNet will encompass four PDTCs (to be supported by a companion FOA, RFA-CA-17-003 ) and a single PDCCC (to be supported by this FOA). In addition, PDXNet will be supported by the NCI Patient-Derived Models Repository (PDMR) at the Frederick National Laboratory for Cancer Research (FNLCR). PDTCs and the PDCCC will be expected to collaborate with PDMR in several areas related to the goals of the program, including the development of optimized standardized procedures, and in sharing of PDX models.

Applications due March 3, 2017

  PDX Development and Trial Centers (PDTCs) (U54) (Deadline: 3/3/17)

PDX Development and Trial Centers (PDTCs) (U54)

This funding opportunity announcement (FOA) solicits applications for PDX (patient-derived xenografts) Development and Trial Centers (PDTCs) to serve as the laboratory research units of the PDX Development and Trial Centers Research Network (PDXNet). The PDXNet is a National Cancer Institute (NCI) program established to coordinate collaborative, large-scale development and pre-clinical testing of targeted therapeutic agents in patient-derived models to advance the vision of cancer precision medicine.

The main goals for PDTCs include:

  • Development of new PDX models and methods for preclinical testing of single agents and drug combinations; and
  • Conducting studies of response of PDX models to novel therapeutic strategies using the newly established models as well as other existing well-characterized PDX models.

It is expected that the outcomes of PDXNet research will be particularly important for the prioritization of combinations of agents in the portfolio of NCI Investigational New Drugs (NCI-IND agents), which are evaluated clinically in the NCI's Experimental Therapeutic Clinical Trials Network (ETCTN).

PDXNet will encompass four PDTCs (to be supported by this FOA) and a single PDX Data Commons and Coordinating Center (PDCCC) (to be supported by a companion FOA, RFA-CA-17-004). In addition, collaboration between PDXNet and the NCI Patient-Derived Models Repository (PDMR) at the Frederick National Laboratory for Cancer Research (FNLCR) will be required as part of this FOA. PDTCs will be expected to collaborate with PDMR in several areas related to the goals of the program, including the development of optimized standardized procedures, and in sharing of PDX models.

Applications due March 3, 2017

  Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01) (Deadline: 3/7/17)

Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (U01)

The purpose of this funding opportunity announcement (FOA) is to stimulate research in the area of PDAC microenvironment with the ultimate goal of understanding the interaction between tumors and the microenvironment. The plan is to design new immunotherapy and combination interventions that would accommodate and build on the distinct characteristics of this interaction. It is expected that the interventions will lead to improved responses in pre-clinical models and clinical evaluation either in NCI-based early phase networks (ETCTN), or by industry or cancer centers.

There is a need to better understand the role of inflammation in the genesis and progression of PDAC, the role of different effectors and suppressors of immune responses, the contribution of tumor stroma with the focus on its heterogeneity, and the function of tumor vasculature. Studying tumor-microenvironment interactions in PDAC should lead to the discoveries of vulnerabilities that could be exploited in the design of immunotherapies such as cancer vaccines, checkpoint inhibition, cellular therapies and their combination with other precision medicine interventions and radiation therapy.

Applications due March 7, 2017

  Canine Immunotherapy Trials and Correlative Studies (U01) (Deadline: 3/7/17)

Canine Immunotherapy Trials and Correlative Studies (U01)

This Funding Opportunity Announcement (FOA) will support canine clinical studies using immunotherapeutic agents and novel drug combinations (such as immune modulators, molecular targeted agents, chemotherapy, and/or radiation) together with laboratory correlative studies that seek to describe characterize and understand the cellular and molecular mechanisms that determine the anti-tumor response (or non-response) in dogs with spontaneous tumors. The FOA will support a network of laboratories and canine clinical trial sites. A companion funding opportunity (see U24 funding opportunity RFA-CA-17-002) will support a coordinating center that will aid in the development, standardization, and conduct of the clinical and laboratory studies as well as data management across the funded U01 sites.

Applications due March 7, 2017

  Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24) (Deadline: 3/7/17)

Coordinating Center for Canine Immunotherapy Trials and Correlative Studies (U24)

This Funding Opportunity Announcement (FOA) will support a coordinating center for a network of cooperative agreements (see U01 FOA RFA-CA-17-001) that will conduct clinical trials in pet dogs with spontaneous tumors and perform laboratory correlative studies associated with the clinical trials.

This FOA will work with the NCI Comparative Oncology Program (COP) of the NCI's Center for Cancer Research as an integral component and will provide statistical support; assist with the development and standardization of clinical protocols and laboratory immune monitoring assays; assist with the implementation of clinical studies in immunotherapy and combination agents including accrual to the trials; manage clinical and correlative data from all U01 sites and their collaborators including immune-related adverse events; facilitate the sharing of agents, specimens, and data; and create an ad hoc steering committee of required expertise--both inside and outside the U01 network, including the PD/PIs of the U01s, representatives of the COP and the NCI Program Official--to ensure that the goals of the network are accomplished.

Applications due March 7, 2017

  Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24) (Deadline: 3/7/17)

Resource Center for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies (U24)

This funding opportunity announcement (FOA) invites applications to establish a Resource Center (RC) for the Consortium for Pancreatic Ductal Adenocarcinoma (PDAC) Translational Studies on the Tumor Microenvironment (Consortium) that has the ultimate goal to design new immunotherapy and combination interventions in PDAC.

The RC will support the administrative coordination of the Consortium, create and support database(s) for data pertinent to the Consortium. It will secure centralized tissue banking for specimens submitted by the members of the Consortium and a virtual biospecimen database that would include all tissue resources of the Consortium. The RC will provide centralized bioinformatics and data analysis support, establish in vivo and in vitro model repositories and distribution units. Lastly, the RC will support meeting and communications coordination among members of Consortium, and form and maintain a Consortium website.

Applications due March 7, 2017

  NLM Administrative Supplements for Informationist Services in NIH-funded Research Projects (Admin Supp) (Deadline: 3/15/17)

NLM Administrative Supplements for Informationist Services in NIH-funded Research Projects (Admin Supp)

These administrative supplements provide funds to active awards of participating Institutes and Centers in order to enhance the storage, organization, management and use of digital research data through the involvement of informationists, also known as in-context information specialists. The purposes of this administrative supplement program are (1) to enhance collaborative, multi-disciplinary basic and clinical research by integrating an information specialist into the research team in order to improve the capture, storage, organization, management, integration, presentation and dissemination of digital biomedical research data; and (2) to assess the impact of the informationist’s participation.

Applications due March 15, 2017

  Cancer Immunologic Data Commons (CIDC) (U24) (Deadline: 3/17/2017)

Cancer Immunologic Data Commons (CIDC) (U24)

The purpose of this funding opportunity announcement (FOA) is to solicit applications for establishment of a Cancer Immunologic Data Commons (CIDC) to provide bioinformatics support as part of a Network for correlative studies in clinical trials involving cancer immunotherapy. The Network will encompass a single CIDC award (to be supported by this FOA) and up to three Cancer Immune Monitoring and Analysis Centers (CIMACs) (to be supported by a companion FOA, RFA-CA-17-005).

The goal of the CIMACs-CIDC Network is to enable systematic incorporation of biomarker studies in NCI-supported early clinical trials for immunotherapy. CIMACs will be responsible for comprehensive analyses of biospecimens from patients for biomarkers relevant to genomic, phenotypic, and functional aspects of responses to immunotherapy. CIDC will serve the bioinformatics needs of the Network, including collection, integration, access, and analysis of data generated from CIMACs. The CIDC will also contribute to the long-term goal of creating publically accessible Data Commons for cancer immune profiling as well as clinical data that will allow integrated analysis across trials and access by the larger immuno-oncology research community.

Applications due March 17, 2017

  Cancer Immune Monitoring and Analysis Centers (CIMACs) (U24) (Deadline: 3/17/2017)

Cancer Immune Monitoring and Analysis Centers (CIMACs) (U24)

This funding opportunity Announcement (FOA) solicits applications for Cancer Immune Monitoring and Analysis Centers (CIMACs) that will serve as laboratory resource conducting correlative studies in clinical trials involving cancer immunotherapy. The CIMACs activities will be facilitated by the Cancer Immunologic Data Commons (CIDC) (to be supported by the companion FOA (RFA-CA-17-006) through biomedical informatics and information technology methodologies suitable for immune-related biomarkers. Together, the CIMACs and the CIDC will be the primary units of the CIMACs-CIDC Network. CIMACs-CIDC Network is intended to serve as infrastructure for correlative studies in NCI-sponsored clinical trials involving cancer immunotherapy to address the critical importance of biomarkers in management of cancer patients.

Specifically, the Network is intended to address scientific and technical aspects of correlative studies across the NCI-supported early Phase (1 and 2) clinical trials in immunotherapy. Each Center within the Network will encompass a multidisciplinary group with basic, clinical, and computational research expertise. Each CIMAC will offer a wide range of molecular and cell-based analyses using state-of-the-art platforms that will lead to informative biomarker tests to tailor immunotherapy to individual patients. The long term goals are to identify molecular biomarkers that define immune response categories to: (1) predict the likelihood of benefit or toxicity from therapies; (2) help develop rational combination therapies to overcome intrinsic or acquired resistance; (3) aid in understanding resistance mechanisms; (4) provide monitoring strategies; and (5) evaluate target inhibition via pharmacodynamic biomarkers. An additional goal for the Network is to advance biomarker development by establishing and promoting public access to data through a controlled access portal.

Applications due March 17, 2017

  Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp) (Deadline: 3/28/2017)

Administrative Supplements to Promote Research Collaborations on Fusion Oncoproteins as Drivers of Childhood Cancer (Admin Supp)

This Administrative Supplement funding opportunity announcement is part of the Cancer Moonshot initiative to accelerate cancer research, and was developed in response to a recommendation from the Blue Ribbon Panel of experts charged with advising the National Cancer Advisory Board on the exceptional scientific opportunities that could be accelerated through this initiative.

Based on the recommendation to intensify research and form highly dynamic and collaborative networks of investigators to advance our understanding of fusion oncoproteins as drivers of childhood cancers, this FOA supports supplemental funds to current NCI-funded research projects for new interdisciplinary collaborations to perform research within the scientific scope of the parent grant that will lead to better understanding of the mechanisms of action of fusion oncoproteins as drivers of childhood sarcomas, brain cancers, and high risk leukemias.

Applications due March 28, 2017

  Tobacco Use and HIV in Low and Middle Income Countries (R01) (Deadline: 4/4/17)

Tobacco Use and HIV in Low and Middle Income Countries (R01)

The purpose of this funding opportunity announcement (FOA) is to encourage research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.

Applications due April 4, 2017

  Tobacco Use and HIV in Low and Middle Income Countries (R21) (Deadline: 4/4/17)

Tobacco Use and HIV in Low and Middle Income Countries (R21)

The purpose of this funding opportunity announcement (FOA) is to encourage exploratory/developmental research focused on tobacco use and human immunodeficiency virus (HIV) infection in low and middle income countries (LMICs). In particular, applications are encouraged that focus on the development and evaluation of tobacco cessation interventions tailored to HIV positive populations, including those with co-morbidities such as tuberculosis (TB), in low-resource settings in LMICs. This FOA provides funding for research planning, intervention delivery, and follow-up activities.

Applications due April 4, 2017

  Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01) (Deadline: 4/11/17)

Fundamental Mechanisms of Affective and Decisional Processes in Cancer Control (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to encourage projects to generate fundamental knowledge of affective processes. Basic affective science projects should have key consequences for single (e.g., cancer screening) and multiple (e.g., adherence to oral chemotherapy regimen) event decisions and behaviors across the cancer prevention and control continuum.

The FOA is expected to encourage collaboration among cancer control researchers and those from scientific disciplines not traditionally connected to cancer control applications (e.g., affective and cognitive neuroscience, decision science, consumer science) to elucidate perplexing and understudied problems in affective and decision sciences with downstream implications for cancer prevention and control.

Applications due April 11, 2017

  Activities to Promote Technology Research Collaborations (APTRC) for Cancer Research (Admin Supp) (Deadline: 4/12/2017)

Activities to Promote Technology Research Collaborations (APTRC) for Cancer Research (Admin Supp)

The National Cancer Institute (NCI) administers two unique programs focused on supporting technology development research that offer transformative potential for advancing cancer research. The Innovative Molecular Analysis Technologies (IMAT) program supports highly innovative, data-generating platforms and methodologies while the Informatics Technologies for Cancer Research (ITCR) program supports powerful data processing and visualization technologies.

To accelerate the development of new enabling cancer technologies, the NCI invites requests for supplemental funding in fiscal years 2017 and 2018 to support and encourage new multidisciplinary scientific collaborations among awardees from these two programs. The goal of the Activities to Promote Technology Research Collaborations (APTRC) is to support new collaborations that bring together complementary technology platforms and methodologies to enhance the capabilities of either in a way that advances cancer research or clinical care. The proposed APTRC activities must be within the overall scope of active parent grants.

Applications due April 12, 2017

  Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01) (Deadline: 5/7/17)

Behavioral Interventions to Address Multiple Chronic Health Conditions in Primary Care (R01)

This funding opportunity announcement (FOA) seeks Research Project Grant (R01) applications that propose to use a common conceptual model to develop behavioral interventions to modify health behaviors and improve health outcomes in patients with comorbid chronic diseases and health conditions. Specifically, this FOA will support research in primary care that uses a multi-disease care management approach to behavioral interventions with high potential impact to improve patient-level health outcomes for individuals with three or more chronic health conditions.

The proposed approach must modify behaviors using a common approach rather than administering a distinct intervention for each targeted behavior and/or condition. Diseases and health conditions can include, but are not limited to: mental health disorders (e.g., depression), diabetes, smoking, obesity, chronic pain, alcohol and substance abuse and dependence, chronic obstructive pulmonary disorder, cancer and hypertension.

Applications due May 7, 2017

  Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01) (Deadline: 5/9/17)

Quantitative Imaging Tools and Methods for Cancer Response Assessment (U01)

The purpose of this Funding Opportunity Announcement (FOA) is to provide a mechanism of support to research organizations interested in clinically translating already optimized quantitative imaging software tools capable of measuring or predicting the response of cancer to clinical therapies, or in translating imaging tools for planning and validating radiation therapy treatment strategies in clinical trials.

The quantitative tools must have been developed and optimized during a performance period in the Quantitative Imaging Network (QIN) or under other separate funding. The proposed research effort should be an extension of the research that successfully completed the tasks of developing and optimizing the chosen software tools or data collection methods intended to facilitate clinical decision making during clinical trials. This FOA is intended to support the efforts of validating those tools in prospective multisite clinical trials in order to test tool performance and to demonstrate that the tool can be integrated into clinical workflow with a minimum of disruption.

Applications due May 9, 2017

  Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3) (Deadline: 5/9/17)

Quantitative Imaging Tools and Methods for Cancer Therapy Response Assessment (UG3/UH3)

This Funding Opportunity Announcement (FOA) encourages research project applications under the cooperative agreement (UG3/UH3) mechanism to address the development, optimization and validation of quantitative imaging (QI) software tools and methods for prediction and/or measurement of response to cancer therapies or for planning and validating radiation therapy treatment strategies in clinical trials.

The scientific scope of this FOA includes:

  • Development and optimization of QI tools and/or methods for treatment planning, predicting or measuring response to therapy as open source tools that will translate into clinical trial decision support;
  • Validation of the optimized tools in clinical settings to demonstrate their value for decision support in ongoing single-site or multi-site clinical trials.

A phased approach that emphasizes each of these activities must be proposed. Investigators must apply for both the UG3 and UH3 phases together in the single application. The UG3 effort is to be used for the development and optimization of QI tools and methods chosen for study by the investigating team, while the UH3 phase is for the validation of the tools/methods developed in the UG3 phase. The UG3 phase can be no more than 2 years in duration, and the total project cannot exceed 5 years. At completion, UG3 projects will be reviewed by program staff. Those that have met their milestones may be administratively considered by NCI program staff for transition to the UH3 validation phase.

Applications due May 9, 2017

  Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01) (Deadline: 5/22/17)

Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R01)

The overarching objectives of this initiative are to understand the etiologic factors and the underlying mechanisms responsible for chronic liver diseases and documented cancer disparities among racial/ethnic minority and socioeconomically disadvantaged populations in the US. For the purpose of this initiative the focus is on the causes for increase in both the incidence and mortality rates of chronic liver disease and cancer among the health disparities populations.

Many potential individual, contextual and structural factors influence health disparities; therefore, this FOA invites applications that include multidisciplinary research to understand the influence of multiple factors that cause liver disease/cancer health disparities and the mechanisms through which they operate. Since the causes of health disparities are complex, applicants are encouraged to focus on the interplay of multiple factors between genetic, behavioral, environmental and structural factors that drives the observed racial/ethnic differences in health outcome. Studies for this initiative may include multi-disciplinary epidemiological, behavioral, or health services projects that leverage understanding of the biological factors that influence chronic liver disease and HCC. In addition, projects can involve primary and/or secondary data collection and analysis. Because the goal of this initiative is to better understand documented racial/ethnic and SES disparities in chronic liver diseases and cancer, studies whose sole purpose is to assess incidence of liver disease/cancer in specific populations or subpopulations are not targeted for support under this FOA.

Projects should include a focus on one or more NIH-designated health disparity populations in the United States, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, sexual and gender minorities and underserved rural populations. For health disparity populations with a significant proportion of immigrants, comparison of health factors between the U.S. and country of origin, length of stay may be considered when appropriate.

Applications due May 22, 2017

  Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21) (Deadline: 5/22/17)

Mechanisms of Disparities in Chronic Liver Diseases and Cancer (R21)

The purpose of the initiative is to support multidisciplinary innovative exploratory and developmental research to understand the underlying etiologic factors and the mechanisms that result in disparities in chronic liver diseases and cancer in the US. This FOA utilizes the Research Project Grant (R21) mechanism, and is suitable for early phase, pilot, or exploratory/developmental projects. Investigators who are interested in proposing larger scale, later phase projects based upon substantial preliminary data should submit applications to the companion FOA PAR-17-151 of identical scientific scope which uses the NIH (R01) grant mechanism.

Many potential individual, contextual and structural factors influence health disparities; therefore, this FOA invites applications that include multidisciplinary exploratory research to understand the influence of multiple factors that cause liver disease/cancer health disparities and the mechanisms through which they operate. Since the causes of health disparities are complex, applicants are encouraged to focus on the interplay of multiple factors between genetic, behavioral, environmental and structural factors that drives the observed racial/ethnic differences in health outcome. Studies for this initiative may include multi-disciplinary epidemiological, behavioral, or health services projects that leverage understanding of the biological factors that influence chronic liver disease and HCC. In addition, projects can involve primary and/or secondary data collection and analysis. Because the goal of this initiative is to better understand documented racial/ethnic and SES disparities in chronic liver diseases and cancer, studies whose sole purpose is to assess incidence of liver disease/cancer in specific populations or subpopulations are not targeted for support under this FOA.

Projects should include a focus on one or more NIH-designated health disparity populations in the United States, which include Blacks/African Americans, Hispanics/Latinos, American Indians/Alaska Natives, Asian Americans, Native Hawaiians and other Pacific Islanders, socioeconomically disadvantaged populations, sexual and gender minorities and underserved rural populations. For health disparity populations with a significant proportion of immigrants, comparison of health factors between the U.S. and country of origin, length of stay may be considered when appropriate.

Applications due May 22, 2017

  Cancer Research Education Grants Program - Courses for Skills Development (R25) (Deadline: 5/25/17)

Cancer Research Education Grants Program - Courses for Skills Development (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Courses for Skills Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, in accordance with the overall mission of the NCI.

Applications due May 25, 2017

  Cancer Research Education Grants Program - Curriculum or Methods Development (R25) (Deadline: 5/25/17)

Cancer Research Education Grants Program - Curriculum or Methods Development (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Curriculum or Methods Development. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, in accordance with the overall mission of the NCI.

Applications due May 25, 2017

  Cancer Research Education Grants Program - Research Experiences (R25) (Deadline: 5/25/17)

Cancer Research Education Grants Program - Research Experiences (R25)

The NIH Research Education Program (R25) supports research education activities in the mission areas of the NIH. The over-arching goal of this NCI R25 program is to support educational activities that complement and/or enhance the training of a workforce to meet the nation's biomedical, behavioral and clinical research needs. To accomplish the stated over-arching goal, this FOA will support creative educational activities with a primary focus on Research Experiences. Applications are encouraged that propose innovative, state-of-the-art programs that address the cause, diagnosis, prevention, and treatment of cancer, rehabilitation from cancer, and the continuing care of cancer patients and the families of cancer patients, in accordance with the overall mission of the NCI.

Applications due May 25, 2017

  Multilevel Interventions in Cancer Care Delivery: Building From the Problem of Follow-up to Abnormal Screening Tests (U01) (Deadline: 5/26/17)

Multilevel Interventions in Cancer Care Delivery: Building From the Problem of Follow-up to Abnormal Screening Tests (U01)

This Funding Opportunity Announcement (FOA) encourages applications that develop and test multilevel interventions to improve follow-up to abnormal screening tests for breast, colorectal, cervical and lung cancers. Improving follow-up to abnormal screening tests is dependent on factors at the individual, team, healthcare system or community setting levels. Appropriate applications for this FOA should propose to intervene at one or more levels, and must measure outcomes at three or more levels, while accounting for interactions that occur between levels.

Applications due May 26, 2017

  Perception and Cognition Research to Inform Cancer Image Interpretation (R01) (Deadline: 5/30/17)

Perception and Cognition Research to Inform Cancer Image Interpretation (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

Applications due May 30, 2017

  Perception and Cognition Research to Inform Cancer Image Interpretation (R21) (Deadline: 5/30/17)

Perception and Cognition Research to Inform Cancer Image Interpretation (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to facilitate research on the perceptual and cognitive processes underlying the performance of cancer image observers in radiology and pathology, in order to improve the accuracy of cancer detection and diagnosis.

This FOA utilizes the Exploratory/Developmental Grant (R21) mechanism, which supports investigation of novel scientific ideas or new model systems, tools, or technologies that have the potential for significant impact on biomedical or biobehavioral research. An R21 grant application needs not have extensive background material or preliminary information.

Applications due May 30, 2017

  Serious Adverse Drug Reaction Research (R01) (Deadline: 6/1/2017)

Serious Adverse Drug Reaction Research (R01)

The objective of this FOA is to encourage research projects addressing current gaps in our knowledge of serious ADRs, particularly those that are idiosyncratic. These gaps exist along the translational spectrum. Potential areas of study include, but are not limited to, basic research into the immunologic, cellular, molecular, and toxicological mechanisms underlying serious ADRs, the identification of biomarkers and other population aspects of genetic susceptibility/pharmacogenomics and epidemiology of serious ADRs, and the development of therapies and interventions to treat and prevent serious ADRs. Within the broad range of objectives outlined above, applications must be within scope of the participating Institutes/Centers delineated below. Potential applicants are encouraged to contact IC scientific representatives for further information.

NCI welcomes applications for pre-clinical, translational, and clinical research on: mechanisms underlying serious ADRs, including organ toxicities and immune-related ADRs, resulting from anti-cancer therapies; discovery and integration of informative biomarkers for prediction, early detection, or monitoring of ADRs; development and validation of clinical assays or tools for measuring these ADR markers; and development of interventions for alleviation of severe and/or chronic ADRs in cancer patients. Other areas of NCI interest include: development, testing, interpretation and the use of patient-reported outcome (PRO) measures to capture symptomatic toxicities, such as fatigue, nausea and neuropathy, in cancer patients; and epidemiologic surveillance over time of serious ADRs.

Applications due June 1, 2017

  Serious Adverse Drug Reaction Research (R21) (Deadline: 6/1/2017)

Serious Adverse Drug Reaction Research (R21)

The objective of this FOA is to encourage exploratory/developmental research projects addressing current gaps in our knowledge of serious ADRs, particularly those that are idiosyncratic. Exploratory and developmental research projects provide support for the early and conceptual stages of a project. These studies may involve considerable risk but may lead to a breakthrough in serious adverse drug reaction research, or to the development of novel techniques, agents, methodologies, models, or applications that could have a major impact on the field. The gaps to be addressed in the FOA exist along the translational spectrum. Potential areas of study include, but are not limited to, basic exploratory/developmental research into the immunologic, cellular, molecular, and toxicological mechanisms underlying serious ADRs, the identification of biomarkers and other population aspects of genetic susceptibility/pharmacogenomics and epidemiology of serious ADRs, and the exploratory development of therapies and interventions to treat and prevent serious ADRs. Within the broad range of objectives outlined above, applications must be within scope of the participating Institutes/Centers delineated below. Potential applicants are encouraged to contact IC scientific representatives for further information.

NCI welcomes applications for pre-clinical, translational, and clinical research on: mechanisms underlying serious ADRs, including organ toxicities and immune-related ADRs, resulting from anti-cancer therapies; discovery and integration of informative biomarkers for prediction, early detection, or monitoring of ADRs; development and validation of clinical assays or tools for measuring these ADR markers; and development of interventions for alleviation of severe and/or chronic ADRs in cancer patients. Other areas of NCI interest include: development, testing, interpretation and the use of patient-reported outcome (PRO) measures to capture symptomatic toxicities, such as fatigue, nausea and neuropathy, in cancer patients; and epidemiologic surveillance over time of serious ADRs.

Applications due June 1, 2017

  Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01) (Deadline: 6/5/17)

Advancing Translational and Clinical Probiotic/Prebiotic and Human Microbiome Research (R01)

The purpose of this funding opportunity announcement (FOA) is twofold: 1. to accelerate translational and clinical Phase I and II a/b safety and efficacy studies for substantiating measurable functional benefits of probiotic/prebiotic components and/or their combinations; and; 2. to understand the underlying mechanisms of their action(s), and variability in responses to these interventions.

This FOA calls for interdisciplinary collaborations across scientific disciplines engaged in microbiome and pro/prebiotic research including, but not limited to: nutritional science, microbiology, virology, microecology and microbiome, genomics, immunology, computational biology, chemistry, bioengineering, as well as integration of omics and computational approaches in DNA technologies.

This FOA will not support phase III clinical trials.

Applications due June 5, 2017

  Early-Life Factors and Cancer Development Later in Life (R01) (Deadline: 6/5/17)

Early-Life Factors and Cancer Development Later in Life (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life. Given that current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait 50 years for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.

Applications due June 5, 2017

  Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01) (Deadline: 6/5/17)

Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R01)

The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse and to develop and test interventions that will reduce overuse in healthcare delivery systems.

Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults.

Applications due June 5, 2017

  Paul Calabresi Career Development Award for Clinical Oncology (K12) (Deadline: 6/15/17)

Paul Calabresi Career Development Award for Clinical Oncology (K12)

This funding opportunity announcement (FOA) encourages applications for institutional research career development (K12) programs from applicant organizations that propose to promote the training and career development of clinical trials researchers. It is intended to increase the number of clinicians (MDs, DOs, PharmDs, nurses with PhDs or equivalent) and non-clinician postdoctoral researchers trained to design and test clinical therapeutic research protocols in clinical trial settings (pilot/Phase I, Phase II, and Phase III clinical trials).     

Applications due June 15, 2017

  Early-Life Factors and Cancer Development Later in Life (R03) (Deadline: 6/16/17)

Early-Life Factors and Cancer Development Later in Life (R03)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life. Given that current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait 50 years for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.

Applications due June 16, 2017

  Early-Life Factors and Cancer Development Later in Life (R21) (Deadline: 6/16/17)

Early-Life Factors and Cancer Development Later in Life (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to stimulate research focused on the role of early-life factors in cancer development later in life. Given that current emerging evidence from limited research indicates a potentially important role for early-life events and exposures in cancer development, it is necessary to better understand 1) the early-life (maternal-paternal, in utero, birth and infancy, puberty and adolescence, and teenage and young adult years) factors that are associated with later cancer development; 2) how early-life factors mediate biological processes relevant to carcinogenesis; and 3) whether predictive markers for cancer risk based on what happens biologically at early-life can be measured and developed for use in cancer prevention strategies.

Markers that predict malignancy or pre-malignant conditions would allow assessment of early-life exposures with relevant outcomes without having to wait 50 years for cancer development. Ultimately, a better mechanistic understanding of how early-life events and exposures contribute to the etiology of cancer later in life will allow for the development of effective interventions during pregnancy or early life that may have a profound impact on cancer prevention.

Applications due June 16, 2017

  Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21) (Deadline: 6/16/17)

Reducing Overscreening for Breast, Cervical, and Colorectal Cancers among Older Adults (R21)

The purpose of this Funding Opportunity Announcement (FOA) is to promote research on interventions, based in healthcare settings, designed to reduce overscreening for breast, cervical, or colorectal cancers among average-risk older adults. While ongoing efforts to promote screening have been successful, there is growing concern that these tests may be overused, thereby subjecting adults to unnecessary risks. Overscreening older adults may be driven by factors at the individual, healthcare team, healthcare system and community organization levels. Therefore, research is needed both to understand the factors that drive overuse and to develop and test interventions that will reduce overuse in healthcare delivery systems.

Research supported by this FOA should propose to intervene at two or more levels, and should measure outcomes at two or more levels, while accounting for interactions that occur between levels. Research supported by this FOA should enhance knowledge and consequences of overscreening to improve the health, independence, and quality of life of older adults.

Applications due June 16, 2017

  Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01) (Deadline: 6/28/17)

Early Phase Clinical Trials in Imaging and Image-Guided Interventions (R01)

This Funding Opportunity Announcement (FOA) is intended to support clinical trials conducting preliminary evaluation of the safety and efficacy of imaging agents, as well as an assessment of imaging systems, image processing, image-guided planning and/or execution therapy, contrast kinetic modeling, 3-D reconstruction and other quantitative tools. As many such preliminary evaluations are early in development, this FOA will provide investigators with support for pilot (Phase I and II) cancer imaging clinical trials, including patient monitoring and laboratory studies. This FOA supports novel uses of known/standard clinical imaging agents and methods as well as the evaluation of new agents, systems, or methods. The imaging and image-guided intervention (IGI) investigations, if proven successful in these early clinical trials, can then be validated in larger studies through competitive R01 mechanisms, or through clinical trials in the Specialized Programs of Research Excellence (SPOREs), Cancer Centers and/or the NCI's National Clinical Trials Network.

Applications due June 28, 2017

  KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research (Deadline: 10/27/17)

KRAS Fellowship – Pancreatic Cancer Action Network | NCI, Frederick National Laboratory for Cancer Research

The KRAS Fellowship provides $100,000 in research funding over a two-year period. The grant term begins on July 1, 2017, and concludes on June 30, 2019. In addition to the research grant, Fellows are provided with $5,000 in travel support plus housing to visit FNLCR.

During the grant term, Fellows are given guest researcher status at FNLCR and are trained and granted access to onsite technology to support their funded research. They also receive support from the RAS Initiative team in planning experimental approaches for their funded project, mentorship from the RAS Initiative leadership and opportunities to participate in scientific lab meetings and workshops and to forge collaborations with other RAS researchers.

Fellows also attend the Pancreatic Cancer Action Network's Annual Scientific Meeting (scheduled for August 17-20, 2017, and dates to be determined in 2018 and 2019). This meeting brings together grant recipients and members of the organization’s Scientific and Medical Advisory Board for research feedback, knowledge exchange, mentorship and collaboration. Support for travel to the annual meeting is provided separate from the Fellowship grant.

Applications due October 27, 2017

National Institutes of Health (NIH)

Open AllClose All
  Time-Sensitive Obesity Policy and Program Evaluation (R01)

Time-Sensitive Obesity Policy and Program Evaluation (R01)

This Funding Opportunity Announcement (FOA) establishes an accelerated review/award process to support time-sensitive research to evaluate a new policy or program that is likely to influence obesity related behaviors (e.g., dietary intake, physical activity, or sedentary behavior) and/or weight outcomes in an effort to prevent or reduce obesity. This FOA is intended to support research where opportunities for empirical study are, by their very nature, only available through expedited review and funding.

All applications to this FOA must demonstrate that the evaluation of an obesity related policy and /or program offers an uncommon and scientifically compelling research opportunity that will only be available if the research is initiated with minimum delay. For these reasons, applications in response to this time-sensitive FOA are not eligible for resubmission. It is intended that eligible applications selected for funding will be awarded within four months of the application due date. However, administrative requirements and other unforeseen circumstances may delay issuance dates beyond that timeline.

Applications due on a continuous basis (once per month)

Department of Defense (DOD)

Foundations & Organizations

Open AllClose All
  American-Italian Cancer Foundation (AICF) (Deadline: 2/28/17)

American-Italian Cancer Foundation (AICF)

AICF is proud to sponsor the work of bright young scientists who perform groundbreaking research in the fields of cancer biology and treatment in competitive labs across the United States.

The Program provides financial support for the post-doctoral research of bright young scientists who pursue research and advanced training in collaboration with mentors at major cancer centers in the United States.

Post-doctoral research fellowships are a critical component in advancing cancer research, as they support talented young scientists with innovative project ideas at a time in their careers when funding from other sources is less certain. AICF's Program differs from most other U.S.-based research fellowship programs in that it focuses on providing opportunities for Italian researchers to train and conduct research at the major cancer centers in the United States.

Eligible applications for an AICF Fellowship include proposals for basic or translational cancer research, as well as clinical research.

Applications due February 28, 2017

  Career Development Award (CDA) - Melanoma Research Foundation (MRF) (Deadline: 3/1/17)

Career Development Award (CDA) - Melanoma Research Foundation (MRF)

MRF is committed to advancing research across the spectrum of melanoma - from prevention through diagnosis, staging and treatment. The MRF proactively partners with the NCI, Congress, the Department of Defense and other foundations to develop and collaborate on a broad agenda for melanoma research that takes full advantage of all opportunities, while also sharing challenges.

All CDA Awards must address one of the Specific Topic Proposals (STPs) identified below.

SPECIFIC TOPIC PROPOSALS (STPs):

The identification of scientific topics that address unmet clinical needs in melanoma research were identified through a series of meetings of multidisciplinary experts from the MRF's Scientific Advisory Committee and Breakthrough Consortium Steering Committee. The following categories are the identified unmet needs in melanoma research selected as STPs for 2017:

  • Prevention: Development of models and biomarkers
  • Identifying mechanisms and respective therapeutic strategies in less common molecular subsets of melanoma
  • Metastases: Dormancy and metastatic progression
  • CNS Metastases: Development of markers of risk and rational therapeutic approaches
  • Response to treatment: Mechanisms and respective biomarkers for predicting response and for monitoring therapeutic response
  • Resistance: Intrinsic/Innate/Primary resistance to immunotherapies in melanoma

Applicants must clearly indicate which of the categories - if any - is being addressed in their application. In all cases, the scientific merit is the most important factor underlying the selection for funding.

The use of relevant genetic models and/or human derived tumor samples is highly encouraged, but not required.

Proposed research must comply with all applicable National Institutes of Health (NIH) animal and human welfare guidelines.

Applications due March 1, 2017

  Established Investigator Awards (EIA) - Melanoma Research Foundation (MRF) (Deadline: 3/1/17)

Established Investigator Awards (EIA) - Melanoma Research Foundation (MRF)

The Melanoma Research Foundation (MRF) is committed to advancing research across the spectrum of melanoma – from prevention through diagnosis, staging and treatment. The MRF proactively partners with the NCI, Congress, the Department of Defense and other foundations to develop and collaborate on a broad agenda for melanoma research that takes full advantage of all opportunities, while also sharing challenges. The EIAs provide funding of up to $100,000 per year for two years to established melanoma researchers, or senior researchers working in closely related fields who wish to move into melanoma research.

Applications are due March 1, 2017

  Medical Student Awards - Melanoma Research Foundation (MRF) (Deadline: 3/1/17)

Medical Student Awards - Melanoma Research Foundation (MRF)

The Melanoma Research Foundation (MRF) is committed to advancing research across the spectrum of melanoma – from prevention through diagnosis, staging and treatment. The MRF proactively partners with the NCI, Congress, the Department of Defense and other foundations to develop and collaborate on a broad agenda for melanoma research that takes full advantage of all opportunities, while also sharing challenges. The MRF is committed to introducing students early in their career to the clinical or research opportunities under the mentorship of an investigator engaged in melanoma research. These awards provide opportunities and funding for medical students to engage in short clinical or laboratory-based research projects focused on better understanding the biology and treatment of melanoma. As such, medical students are encouraged to submit applications for the $3,000 award for 1 year of research.

Applications due March 1, 2017

  Moore Inventor Fellows - The Gordon and Betty Moore Foundation (Deadline: 3/1/17)

Moore Inventor Fellows - The Gordon and Betty Moore Foundation (Institution) (Foundation)

In 1965, Gordon Moore predicted the doubling of components on an integrated circuit every 18 months. From careful observation of an emerging trend, Moore extrapolated that computing would dramatically increase in power, and decrease in relative cost, at an exponential pace. This observation helped fuel the technological advancement and acceleration we have seen in the past 50 years.

With the creation of the Moore Inventor Fellows, the foundation hopes to enable breakthroughs that accelerate progress over the next 50 years. This new fellowship program recognizes early-career innovators at U.S. universities with a high potential to accelerate progress in scientific research, environmental conservation and patient care.

Each fellow will receive a total of $825,000 over three years to drive their invention forward, including $50,000 per year from their home institution as commitment to these outstanding individuals. Beginning with these five fellows in 2016, the foundation will invest nearly $34 million during the next ten years to support 50 Moore Inventor Fellows.

Institutional Applications due January 17, 2017

Foundation Applications due March 1, 2017

  Translational Research Program | Leukemia and Lymphoma, Familial Platelet Disease (FPD) / RUNX1 and Myeloma (Deadline: 3/1/17)

Translational Research Program | Leukemia and Lymphoma, Familial Platelet Disease (FPD) / RUNX1 and Myeloma

The Leukemia & Lymphoma Society (LLS) and the Babich Family Foundation/RUNX1 Research Program are partnering to launch a competitive grant to advance new therapies for, and greater understanding of familial platelet disorders associated with RUNX1 mutations that lead to acute myelogenous leukemia. The program is focused on addressing translational research with a total of $1.8 million; 3 grants will be awarded up to $600,000 each. The applications will be evaluated by a dedicated team of experts and ranked separately from our normal Leukemia and Lymphoma TRP applications.

Applications are sought proposing novel approaches to the prevention, diagnosis or treatment of hematological malignancies and related pre-malignant conditions. Proposals should be based on molecular, cellular or integrated systems findings and be conceptually innovative. The application should have a clear plan for the clinical translation of the studies proposed and the results expected. This feature will be an important consideration of the review process.

This program is intended to provide support over an initial three-year period. Two additional years may be available through the competitive, peer-reviewed TRP Renewal process to solidify progress made in the initial award and further support a clinical trial. To be considered for a TRP renewal award, a clinical protocol for a Phase I or Phase II clinical trial based on the initial Translational Research Program grant must be submitted to the institution's IRB for approval and the work must be a direct result of the funded TRP award.

Applications due March 1, 2017

  Damon Runyon Cancer Research Foundation (Deadline: 3/15/17)

Damon Runyon Cancer Research Foundation

The Damon Runyon Cancer Research Foundation has joined together with the Sohn Conference Foundation, dedicated to curing pediatric cancers, to establish the Damon Runyon-Sohn Pediatric Cancer Fellowship Award. This award provides funding to basic scientists and clinicians who conduct research with the potential to significantly impact the prevention, diagnosis or treatment of one or more pediatric cancers.

Candidates must apply for the fellowship under the guidance of a Sponsor. In addition to aiding in the planning, execution and supervision of the proposed research, the Sponsor's role is to foster the development of the Fellow's overall knowledge, technical and analytical skills, and capacity for scientific inquiry. The Sponsor is also expected to assist the Fellow in attaining his/her career goals.

The proposed research and training environment should represent a new opportunity for the candidate to expand his/her scientific skill set. Direct extensions of the candidate's graduate work (in approach, technique or exact area of study) will not be funded.

Postdoctoral training in the same institution in which the applicant received his/her degree is discouraged, particularly if it is in the same department.

Applications due March 15, 2017

  Distinguished Scientist Award (DSA) | The Sontag Foundation (Deadline: 3/15/17)

Distinguished Scientist Award (DSA) | The Sontag Foundation

This award seeks to provide career and research support to early career scientists who demonstrate outstanding promise for making scientific and medical breakthroughs in the field of brain cancer research.

Recipients of the award are inspired individuals with projects that show potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer. Applicant's career track and proposed research should demonstrate potential to generate new knowledge relating to causes, cure or treatment of primary brain tumors/brain cancer.

Applications due March 15, 2017

  CHEST Foundation Research Grant in Lung Cancer (Deadline: 3/31/17)

CHEST Foundation Research Grant in Lung Cancer

Applications must address research that leads to improved medical and/or surgical detection, treatment, and/or cure of lung cancer. Higher-level translational research project preferred (T1-T5); basic (cellular or animal) research projects will not be considered.

Applications due March 31, 2017

  Prostate Cancer Foundation (PCF) (Deadline: 4/24/17)

Prostate Cancer Foundation (PCF)

The Prostate Cancer Foundation (PCF) is pleased to announce a Request for Applications for PCF Challenge Awards for investigations of metastatic, lethal prostate cancer. These awards will be funded depending on the level of innovation in applications received. High risk, currently unfunded projects are most desired.

PCF Challenge Awards:

  • Team science awards are composed of at least three (3) investigators from non-profit academic research centers, including one young investigator (see PCF Challenge Award Team requirements below).
  • Support large-scale research projects concerning metastatic, lethal prostate cancer over a duration of two years.
  • Provide up to a total of $1 million per team.
  • Cover only direct research costs and travel to the Annual PCF Scientific Retreat.

Research proposals in the following topic areas are preferred:

  • Immunotherapy for the treatment of metastatic, lethal prostate cancer.
  • Targeted radionuclide therapy for advanced prostate cancer.
  • New systemic treatments for metastatic, lethal prostate cancer including those targeting the currently `undruggable'.
  • First-in-field research on new targets for systemic treatment of metastatic, lethal prostate cancer.
  • Mechanisms of resistance to current and investigational drugs targeting the androgen receptor and androgen axis, immune system and chemotherapy.
  • Correlative research around either clinical trials of novel agents or strategies or standard of care.
  • Developing or validating biomarkers that guide therapy in patients or further our understanding of the mechanisms by which therapies work.
  • Tumor microenvironment signaling related to cancer progression including the immune component.
  • New bioinformatics technologies for analysis of genomic data.

Applications due April 24, 2017

  Elsa U. Pardee Foundation (Deadline: 4/30/17)

Elsa U. Pardee Foundation

The Elsa U. Pardee Foundation funds investigators proposing research directed toward identifying new treatments or cures for cancer. The foundation particularly encourages grant applications for a one-year period which will allow establishment of capabilities of new cancer researchers, or new cancer approaches by established cancer researchers. It is anticipated that this early stage funding by the foundation may lead to subsequent and expanded support using government agency funding. Project relevance to cancer detection, treatment, or cure should be clearly identified.

Applications due April 30, 2017

  LUNGevity Career Development Awards for Translational Research (LUNGevity Foundation) (Deadline: 5/5/17 - by invitation only)

LUNGevity Career Development Awards for Translational Research (LUNGevity Foundation)

LUNGevity Foundation is a 501(c)(3) philanthropy specifically focused on funding research for the early detection and successful treatment of lung cancer. LUNGevity's mission is to improve mortality rates of lung cancer patients through the development of protocols and tools for early detection of lung cancer, early intervention in the disease progression, and targeted therapeutics, including immuno-oncology. LUNGevity focuses on translational science.

LUNGevity's Career Development Awards for Translational Research program was created with one goal: to support future research leaders who will keep the field of lung cancer research vibrant with new ideas. Research projects are restricted to translational lung cancer research, and the applicant must demonstrate the translational relevance of the research proposed. The CDAs are mentored awards; a mentoring plan will be part of the required submission.

High-risk, high-return proposals will receive equal consideration. Translational research includes epidemiology studies, and LUNGevity especially encourages clinical correlative studies. Proposed projects must make use of human biopsies or samples. In vivo primary tumor explants meet these criteria, but xenografts from established cell lines do not. Translational research includes epidemiologic, clinical/correlative, or thoracic surgical research. The use of existing resources is encouraged, including libraries of compounds or probes, tissue or bio-specimen repositories, and other existing sets of tissue, blood, or images. It is strongly encouraged that those applying have direct and immediate access to the bio-specimens necessary to complete their research.

Applications due May 5, 2017 (by invitation only)

  Educational Grants (Bayer AG; Bayer USA Foundation) (Deadlines: 8/8/17 for Oncology; 10/1/17 for Generic Education)

Educational Grants (Bayer AG; Bayer USA Foundation)

The goal of the contributions and educational grants initiatives is to promote the general prevention and treatment of disease and illness. Bayer strategically focuses its funding in support of research, education and patient support. As a commitment to improving patient care and providing valuable information to the medical and broader healthcare community, Bayer HealthCare will accept the following grant requests:

  1. Healthcare professional education
  2. Patient advocacy and Consumer education programs (e.g., disease-state education and awareness, screenings, camps, etc.)

Areas of Support:

  • Dermatology
  • Radiology
  • Hematology-Hemophilia
  • General Medicine (Pulmonology/Cardiology/Infectious Disease/Non-Cystic Fibrosis Bronchiectasis)
  • Neurology
  • Women's Health

Oncology:

  • Advanced Prostate Cancer
  • Colorectal Cancer
  • Gastrointestinal Stromal Tumor
  • Hepatocellular Carcinoma
  • Thyroid Cancer

Applications due August 8, 2017 (Oncology); October 1, 2017 (Generic Education)

  St Baldrick’s Foundation (SBF) (Deadline: 8/31/17)

St Baldrick’s Foundation (SBF)

These grants are not for a specific research project, but rather for resources to allow more research to be done. They support institutions with the potential for more participation in childhood cancer clinical trials, but which currently lack necessary resources (primarily support for Clinical Research Associates). Infrastructure grants are designed to provide an infusion of funds to enable an institution to acquire the personnel (i.e., a clinical research associate) or resources it needs to reach its potential in broader clinical trial participation. The applicant should indicate how ongoing personnel costs will be funded in future years.

Applications due August 31, 2017

  Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G. (Deadline: TBA)

Graduate Training in Disparities Research (GTDR) | Komen for the Cure, Susan G.

Graduate Training in Disparities Research (GTDR) Grants are intended to establish and/or to sustain a training program for graduate students who are seeking careers dedicated to understanding and eliminating disparities in breast cancer outcomes across population groups.

By providing funding to outstanding training programs, Komen seeks to ensure that a diverse pool of highly trained scientists will emerge as the next generation of leaders in the field of breast cancer research focused on disparities in breast cancer outcomes.

The research training program should be designed to meet the following goals:

  • Attract graduate students, specifically those from populations affected by disparities in breast cancer outcomes, into research careers.
     
  • Empower these students with the skills and knowledge necessary to effectively explore the causes of differential breast cancer outcomes and develop interventions to reduce and eliminate such disparities.

Deadline TBA

  Distinguished Scholars | Lustgarten Foundation

Distinguished Scholars | Lustgarten Foundation

The Distinguished Scholars program supports world-class scientists, who are at the top in their field, and are at the forefront of today's most exciting breakthroughs in pancreatic cancer research. Selected by The Lustgarten Foundation's Scientific Advisory Board (SAB), each grantee will receive $5 million in funding over the next five years, enabling these scientists to purse high-risk high-reward science, dedicate more of their time and focus to pancreatic cancer research, and accelerate a path to a cure.

The Distinguished Scholar Award is given on a discretionary basis and is not part of the annual grant program.

  Komen Southeast Wisconsin's Small Grant Program

Komen Southeast Wisconsin's Small Grant Program

Any non-profit organization in the Komen Southeast Wisconsin service area can apply for up to $5,000 for a small pilot or capacity-building breast health program grant. These grants are for organizations interested in beginning a new program or testing new ideas that will increase the innovative capacity and effectiveness of breast health programs that serve low income and uninsured women.

Small Grants are available in two categories:

  1. Education/Outreach Grants will support the development of breast cancer programs or projects.
     
  2. Capacity Building/Technical Assistance Grants will provide funding to increase the efficiency and effectiveness of an organization's ability to provide services by redesigning processes, implementing new practices, or developing collaborations or partnerships.

Applications due on a continuous basis throughout funding cycle

  Pediatric Low Grade Astrocytomas Foundation (PLGA)(Applications continuous)

Pediatric Low Grade Astrocytomas Foundation (PLGA)

The number one priority of A Kids' Brain Tumor Cure Foundation is to act as a catalyst for researchers world-wide to turn their attention to the area of pediatric low grade glioma brain tumor research and to award research grants for the most promising programs and studies. The hope is that this research will lead to a better understanding of the causes of PLGA as well as the discovery of more effective treatments and a cure for the most common forms of children's brain tumors.

Proposals related to basic and translational* projects that can advance understanding of the underlying biology of the development and treatment of PLGA tumors will be considered.

*NIH definition of translational research: the process of applying ideas, insights, and discoveries generated through basic scientific inquiry to the treatment or prevention of human disease.

Applications continuous

  SWOG Trial Support (STrS) – The Hope Foundation (Applications continuous)

SWOG Trial Support (STrS) – The Hope Foundation

SWOG's mission is to improve the practice of cancer medicine in preventing, detecting, and treating cancer, and to enhance the quality of life for cancer survivors, primarily through design and conduct of clinical trials. SWOG is a National Cancer Institute-supported network of more than 5,000 cancer researchers at more than 650 institutions in the U.S., Canada, and beyond. Additional educational and cancer research support is provided by SWOG's non-profit, philanthropic partner, The Hope Foundation.

STrS is a peer-reviewed program administered by The Hope Foundation in conjunction with SWOG. STrS is designed to support trial components that need supplemental funding during patient enrollment in a SWOG study. Qualifying components may include things that are outside of the SWOG-supported norm, such as atypical requests for tissue and/or data, or provision of materials to trial sites.

Applications continuous

Pancreatic Cancer Action Network

Institutional

MCW – Cardiovascular Center (CVC) (Deadline: 5/1/17)

MCW – Cardiovascular Center (CVC) (PDF)

As many of you know, the Cardiovascular Center (CVC) was visited last May by an External Scientific Advisory Board (ESAB) composed of international experts in cardiovascular research who provided the CVC with key recommendations in early Fall to further the CVC’s mission and vision. This report, along with feedback from our Internal Scientific Advisory Board (ISAB), institutional leadership, and from our Town Hall Meetings and informal discussions, has resulted in the following exciting funding opportunities that are made possible by the CVC’s parent award from the Advancing a Healthier Wisconsin Endowment Research and Education Program (AHW-REP), philanthropic contributions to the CVC, collaborative efforts with MCW’s Cancer Center, and the Dean’s institutional funds.

The CVC is pleased to offer funding to CVC members for multiple “Signature Program Pre-PPG” awards including two “Pre-PPG Awards” with an emphasis on Cardio-Oncology in collaboration MCW Cancer Center. The primary goal of the Pre-PPG awards is to elevate our Signature Programs to the next medal level (from Bronze to Silver or Silver to Gold) by investing in team science that will produce program project grants or similar extramural awards. This new programmatic focus is a priority for the CVC as we shift from our exclusive support of smaller pilot grants awarded to individual PIs. Notwithstanding, we are offering two pilot grants, which are supported by the Dr. Michael Keelan, Jr., MD, Research Foundation, for eligible junior or mid-career investigators without current R01-equivalent funding. We especially encourage applications from clinical faculty for this funding mechanism.

Detailed application materials will be distributed soon.

CVC Members: Please RSVP and attend the CVC’s Town Hall Meeting next Wednesday, February 22, from 12-1:30 p.m. in H4950 as we will be discussing and answering questions about these funding opportunities.

Applications due May 1, 2017

Other

Open AllClose All
  Bladder Cancer Advocacy Network (BCAN) (Deadline: 3/1/17)

Bladder Cancer Advocacy Network (BCAN)

This Award is intended to support the development of outstanding research scientists and clinical cancer research investigators who have demonstrated a commitment to improving the understanding and treatment of bladder cancer. Investigators may be working in basic, translational, clinical, epidemiologic, bioengineering or any other field, but must be working in a research environment capable of supporting transformational bladder cancer research. The project must be bladder cancer specific (including upper tract urothelial carcinoma).

Applications due March 1, 2017

  Research Grant Program: A-T Post Doctoral Fellowship Award (Deadline: 3/1/17)

Research Grant Program: A-T Postdoctoral Fellowship Award

Ataxia-telangiectasia, or A-T, is a rare genetic disease that attacks children, causing progressive loss of muscle control, immune system problems, and a high rate of cancer. A-T affects a large variety of systems in the body, causing symptoms that affect health and daily living.

The A-T Children's Project strives to assist respected scientists around the world in developing a clearer understanding of A-T. The A-T Children's Project is determined to find a timely cure, or life-improving treatments, for this serious disease. Postdoctoral fellowships are available.

The A-T Children's Project provides competitive grant awards for basic and translational research grants related to A-T.

The A-T Children's Project is currently focusing its funding efforts on proposals that apply innovative and novel strategies for suggesting, developing and evaluating specific disease-modifying and symptomatic interventions with an emphasis on:

  • translational (bench to bedside) research
  • clinical studies

Applications due March 1, 2017

  Specialized Center of Research Program | Leukemia & Lymphoma Society (Deadline: 3/1/17)

Specialized Center of Research Program | Leukemia & Lymphoma Society

LLS's Specialized Center of Research (SCOR) grant program is intended to bring together established investigators from one or several institutions to develop a focused research program, foster new interactions and cooperation, and enhance interdisciplinary research among the participants. The overall goal of this mechanism is to enhance the development of innovative strategies for the treatment, diagnosis or prevention of hematological malignancies. Strategies that move discoveries from the bench to the clinic are of high importance as are integrated translational projects.

Applications due March 1, 2017

  Innovation Grant: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF) (Deadline: 3/6/17)

Innovation Grant: Alex's Lemonade Stand Foundation for Childhood Cancer (ALSF)

The overall objectives of this grant are to advance cell and gene therapy into the causes, treatment and prevention of all types of cancer by promoting development of novel and innovative studies by young investigators. The emphasis of this initiative is to promote basic and pre-clinical research approaches utilizing cells and genes as medicine. ACGT will direct its grants into areas of cell and gene therapy research that have demonstrated great promise.

The seven main areas of research ACGT will support are:

  1. Tumor-Specific Replicating Viruses and Bacteria
  2. Anti-angiogenesis
  3. Immune-modulatory Therapy and Cancer Vaccines
  4. Oncogene/Suppressor Oncogene/Apoptosis Directed Therapy 9
  5. Tumor Targeting and Vector Development
  6. Cancer Stem Cell Directed Therapy
  7. Other Gene/Cell based Therapies

Applications due March 6, 2017

  Independent Grants for Learning & Change (IGL&C): Track 2 - Call for Grant Applications (CGA) - Knowledge Gaps for Pharmacists in CDK 4/6 Therapies for Advanced or Metastatic Breast Cancer Treatment (Pfizer, Inc.) (Deadline: 3/22/17)

Independent Grants for Learning & Change (IGL&C): Track 2 - Call for Grant Applications (CGA) - Knowledge Gaps for Pharmacists in CDK 4/6 Therapies for Advanced or Metastatic Breast Cancer Treatment (Pfizer, Inc.)

The mission of Pfizer Independent Grants for Learning & Change (IGL&C) is to partner with the global healthcare community to improve patient outcomes in areas of mutual interest through support of measurable learning and change strategies. "Independent" means that the projects funded by Pfizer are the full responsibility of the recipient organization. Pfizer has no influence over any aspect of the projects and only asks for reports about the results and the impact of the projects in order to share them publicly.

Through this CGA Pfizer encourages organizations to submit grant requests that, if funded, will support education in a specific disease state, therapeutic area, or broader area of educational need. Educational activities should not be focused on products specific to Pfizer.

Specific Area of Interest for this CGA: It is our intent to support continuing professional development programs for pharmacists and pharmacy managers involved in the treatment of patients with advanced or metastatic breast cancer.

Clinical Area: Advanced or Metastatic Breast Cancer: CDK 4/6 Inhibition

Applications due March 22, 2017

  2017 ASPIRE Oncology/Hematology Research Awards – Advanced Breast Cancer (Deadline: 3/31/17)

2017 ASPIRE Oncology/Hematology Research Awards – Advanced Breast Cancer

The mission of the ASPIRE Awards program is to support clinical research involving select Pfizer compounds in the fields of Oncology and Hematology through a competitive grants program. This program is to support continuous medical research to maximize the available therapies by improving medical knowledge and clinical management of the disease. Pfizer invites investigators to apply for the 2017 ASPIRE Oncology & Hematology Research Awards through submission of innovative clinical research proposals designed to accomplish the mission of advancing knowledge of select Pfizer compounds in the treatment and disease management of breast cancer. Pfizer is interested in supporting 3-5 clinical studies of palbociclib in advanced breast cancer, focusing in the following areas:

  • In hormone receptor positive (HR+) advanced breast cancer, optimal clinical management and/or nursing management that addresses or improves patient compliance and convenience and/or patient reported outcomes, such as management of non-hematological side effects, bone only disease, and other supportive measures, during palbociclib treatment. Proposals may be a clinical trial, a nursing focused study, or a non-interventional retrospective study under this category
  • In HR+ advanced breast cancer, safety and efficacy profile of palbociclib in combination with hormone therapy, chemotherapy, or other modality in particular patient populations, such as patients with substantial tumor burden, with disease in liver, or with co-morbidities. Safety monitoring should be a significant part of the proposal
  • In HR+ advanced breast cancer, clinical exploration of the role of palbociclib based combination in post palbociclib/hormone therapy in appropriate MBC patients
  • In HER2+ advanced breast cancer patients, safety and efficacy profile of palbociclib in combination with T-DM1 in patients who previously received trastuzumab and a taxane

In addition, the following would be of interest: incorporation of a correlative/biomarker component into the proposed clinical study using paired biopsy samples (e.g. pre- and post- treatment), liquid biopsy, or PK/PD biomarkers to explore potential mechanism of action, as well as sensitivity and resistance mechanisms.

Applications due March 31, 2017

  2017 ASPIRE Oncology/Hematology Research Awards – Advanced Breast Cancer (Deadline: 3/31/17)

2017 ASPIRE Oncology/Hematology Research Awards – Advanced Breast Cancer

The mission of the ASPIRE Awards program is to support clinical research involving select Pfizer compounds in the fields of Oncology and Hematology through a competitive grants program. This program is to support continuous medical research to maximize the available therapies by improving medical knowledge and clinical management of the disease. Pfizer invites investigators to apply for the 2017 ASPIRE Oncology & Hematology Research Awards through submission of innovative clinical research proposals designed to accomplish the mission of advancing knowledge of select Pfizer compounds in the treatment and disease management of acute leukemia. Pfizer is interested in supporting 1-2 studies of each of the following compounds in acute leukemia, focusing in the following areas:

Inotuzumab Ozogamicin

  • Defining the optimal sequencing and dosing of inotuzumab with other treatment options
  • Evaluating the impact of inotuzumab on immune cell functions and identifying immune-related biomarkers
  • Clarifying the role of MRD in the treatment relapsed and refractory Acute Lymphoblastic Leukemia
  • Identifying the early onset biomarkers for liver toxicities and VOD/SOS in inotuzumab-treated patients and exploring preventive, monitoring, and therapeutic measures
  • Exploring the impact of cytogenetic abnormalities or other genomic factors to inotuzumab clinical outcome

Gemtuzumab Ozogamicin

  • Evaluating gemtuzumab fractionated dosing regimen in combination or in sequence with novel agents (eg, targeted agents or immunotherapies) and/or HSCT in previously untreated patients with AML and identification of biomarkers guiding the choice of combination therapies and treatment settings
  • Evaluating gemtuzumab fractionated dosing regimen in combination with low intensity regimens (eg. decitabine, 5-azacitadine) in previously untreated patients with AML
  • Evaluating and optimizing gemtuzumab fractionated dosing regimen as monotherapy or in combination with other agents in patients with relapse AML
  • Evaluating gemtuzumab fractionated dosing regimen in combination with conventional or novel agents in patients with APL
  • Scientific studies involving gemtuzumab focused on the following topics: impact of genetic polymorphism in CD33 on behavior and clinical outcomes; modulation of CD33 by therapy and impact on dosing schedule; biomarkers predicting response/non-response; understanding mechanism of resistance; contemporary approaches to MRD monitoring and correlation with response/duration of remission

Palbociclib

  • Evaluating safety and efficacy profile of palbociclib containing regimen in acute leukemia adult patients or pediatric patients (who are able to swallow pill)

Applications due March 31, 2017

  Irvington Postdoctoral Fellowships (Cancer Research Institute) (Deadline: 4/1/17)

Irvington Postdoctoral Fellowships (Cancer Research Institute)

The program supports qualified individuals who wish to receive training in cancer immunology.

The Institute seeks hypothesis driven, mechanistic studies in both immunology and tumor immunology. The applicant and sponsor must clearly state the potential of the proposed studies to directly impact our understanding of the immune system's role in cancer risk, tumor initiation, progression, metastasis, host response to tumors and/or the treatment of cancer.

Fellows work and continue their training under the guidance of a world-leading immunologist, who mentors the fellow and prepares him or her for a productive and successful career in cancer immunology.

An eligible project must fall into the broad field of immunology and must show relevance to solving the cancer problem. Proposals that do not encompass both these areas will not be considered.

Applications due April 1, 2017

  PSC Partners Seeking a Cure (Deadline: 4/1/17)

PSC Partners Seeking a Cure

PSC Partners Seeking a Cure is a 501(c)(3) nonprofit organization whose mission is to provide education and support to PSC patients, families and caregivers and to raise funds to research causes, treatments and cures for primary sclerosing cholangitis. PSC Partners offers grants to conduct research that addresses an important and novel, basic or clinical research question related to PSC and closely associated diseases (such as inflammatory bowel diseases (IBD), ulcerative colitis (UC) or Crohn's disease) as they relate to PSC. The applicant must be at an academic institution with an interest in pursuing PSC as an indication for treatment. The purpose is to encourage investigators to conduct research in promising new areas with the goal that data generated will lead to federal (NIH) funding.

PSC Partners Seeking a Cure is particularly interested in funding research projects that have the potential to discover a cure for this disease, and/or identify novel therapies that may significantly delay time to liver transplantation, prevent disease recurrence following liver transplantation, and/or improve the quality of life of those with PSC. PSC Partners understands that much fundamental research is necessary to discover the environmental factors that may trigger this disease in genetically susceptible individuals, and therefore we would like to encourage research proposals aimed at identifying the gene-environment interactions contributing to disease initiation and progression. PSC Partners recognizes that studies with animal models may be appropriate to address these fundamental questions. We are interested in funding research that explores PSC-related diseases (IBD, UC, and Crohn's disease) in ways that they impact, enable, or perhaps cause PSC. PSC Partners encourages research that will be complementary to the goals and objectives of the International PSC Study Group, including investigation of the functional roles of genes associated with susceptibility to and severity of PSC. Other priority areas for research include the mechanisms of PSC pathogenesis and colorectal and cholangiocarcinoma carcinogenesis as well as strategies for prevention. Applications focused on assessing and improving the quality of life of PSC patients are also encouraged. Proposals that have little relevance to PSC will not be considered for funding. We strongly encourage interdisciplinary collaborations and the sharing of resources as a means of accelerating progress in PSC research. If the proposal includes a specific plan for sharing of results and resources (such as DNA), this will result in a more favorable review. Applications addressing PSC in children are strongly encouraged.

Applications due April 1, 2017

  Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families (ACS) (Deadline: 4/3/17)

Pilot and Exploratory Projects in Palliative Care of Cancer Patients and Their Families (ACS)

Pilot data are typically needed before funding agencies (e.g., NIH, VA or the American Cancer Society) will consider funding a research project. In an effort to support clinician investigators conducting patient-oriented research in palliative care, the Society, in parallel with the National Palliative Care Research Center (NPCRC), is soliciting applications for pilot/exploratory research grants in palliative care of cancer patients and their families. These grants will generate the pilot data necessary to maximize an investigator's chances of competing successfully for larger grants.

This RFA provides funding for investigators performing pilot and exploratory research studies whose purpose is to test interventions, develop research methodologies, and explore novel areas of research in palliative care of cancer patients and their families. A condition of funding is a clearly defined plan as to how the investigator will use the results of the project to develop larger, extramurally funded research projects.

This RFA is limited to applications that focus on palliative care research projects for seriously ill cancer patients and their families in three specific areas:

  1. Exploring the relationship of pain and other distressing symptoms on quality and quantity of life, independence, function, and disability and developing interventions directed at their treatment in patients with advanced and chronic illnesses;
  2. Studying methods of improving communication between adults living with serious illness, their families and their health care providers;
  3. Evaluating models and systems of care for patients living with advanced illness and their families.

Applications due April 3, 2017

  The Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services (ACS) (Deadline: 4/3/17)

The Role of Health Policy and Health Insurance in Improving Access to and Performance of Cancer Prevention, Early Detection, and Treatment Services (ACS)

Purpose: A call for research that evaluates the impact of the many changes now occurring in the healthcare system with a particular focus on cancer prevention, control, and treatment. Efforts focusing on improving access to care may also impact inequities that contribute to health disparities. New health public policy initiatives such as the new federal and state marketplaces that have expanded insurance coverage, as well as Medicaid expansion in some states, create natural experiments ripe for evaluation. Research to be funded by this RFA should focus on the changes in national, state, and/or local policy and the response to these changes by healthcare systems, insurers, payers, communities, practices, and patients.

The association is keenly interested in supporting rapid learning research to study the effects of health policy changes on patients, providers, and health systems. This includes but is not limited to:

  • Facilitators and barriers to care;
  • Unintended consequences;
  • Differential experiences and outcomes of patients seeking or receiving care;
  • Best practice models for quality care; and,
  • Economic Impact

Applications due April 3, 2017

  All-Priorities' Research Call Project Grants (DEBRA International) (Deadline: 4/19/2017)

All-Priorities' Research Call Project Grants (DEBRA International)

The current research priorities are:

  • Improve the understanding of the biology and genetics of all forms of Epidermolysis bullosa (EB), as better understanding can lead to new approaches to diagnose and treat EB
  • Work towards the development of therapies (including possible gene-therapies, cell-therapies, drug therapies or protein therapies)
  • Understand the nature of wound healing and the development of skin cancer in EB, and seek to develop better treatments and prevention strategies
  • Support clinical care research to improve the management of EB through symptom relief

Subject to funding availability, allocation of funds will recognize an equal prioritization of the research areas, while adhering to the core principle of funding the best research, identified by MSAP as meeting the criteria of scientific quality, feasibility and patient benefit.

DEBRA International welcomes proposals for co-funding with other organizations, including government, academia, industry or other charities.

DEBRA will not, however, fund generic technology development costs not closely related to a specific EB therapeutic approach.

Applications due April 19, 2017

  PCORI Funding Announcement: Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes (Deadline: 5/17/17)

PCORI Funding Announcement: Pragmatic Clinical Studies to Evaluate Patient-Centered Outcomes

PCORI seeks to fund pragmatic clinical trials, large simple trials, or large-scale observational studies that compare two or more alternatives for addressing prevention, diagnosis, treatment, or management of a disease or symptom; improving healthcare system-level approaches to managing care; communicating or disseminating research results to patients, caregivers, or clinicians; or eliminating health or healthcare disparities.

Proposed studies must address critical clinical choices faced by patients, their caregivers, clinicians, or delivery systems. They must involve broadly representative patient populations and be large enough to provide precise estimates of hypothesized effectiveness differences and to support evaluation of potential differences in treatment effectiveness in patient subgroups.

For this solicitation, applicants are not required to demonstrate that patients and other stakeholders are already engaged as research team members at the time an application is submitted. However, applicants should outline how patients and other stakeholders will participate as partners in various phases of the proposed research, once awarded. Applicants should describe their plan to form a Study Advisory Committee (SAC)[1] or other appropriate engagement body, to ensure that a broad spectrum of patients and other stakeholders advise and assist the research team with refining the study questions, outcomes, and protocols. These patients and other stakeholders must include national or regional organizations that represent—at a minimum—patients, caregivers, clinicians, policy makers, and other healthcare system stakeholders. Additional representation may be recommended in collaboration with PCORI, including individual patients with lived experience and other relevant stakeholders, such as scientific and methodological experts.

Applications due May 17, 2017

  Investigator's Award in Clinical Translation of Gene Therapy for Cancer: Investigator's Award in Clinical Translation of Cell and Gene Therapy for Cancer (ACGT) (Deadline 5/22/17)

 

Investigator's Award in Clinical Translation of Gene Therapy for Cancer: Investigator's Award in Clinical Translation of Cell and Gene Therapy for Cancer (ACGT)

ACGT funds research aimed at furthering the development of cell and gene therapy approaches to the treatment of cancer. To this end, ACGT offers awards to support research in clinical translation of cell and gene therapy for cancer.

ACGT RESEARCH OBJECTIVES

A number of cell and gene therapy approaches for cancer have been shown to be efficacious and safe in laboratory animal models in the recent years, but their translation into clinical trials has been hindered by a lack of resources. Recognizing this critical need, ACGT is accepting grant applications to produce and release-testing of the clinical trial agents under cGMP, conduct the necessary pre-clinical pharmacological and toxicological studies in appropriate animal models, and/or conducting the clinical translational trials in patients in support of an Investigative New Drug (IND) application to the FDA. While the unambiguous demonstration of PRECLINICAL TREATMENT EFFICACY DATA IN TUMOR-BEARING ANIMALS in cancer treatment by cell and gene therapy is a pre-requisite, entering into the clinical trial during the funding period is also a requirement. Applications that do not include this specific aim will be deemed unresponsive to the RFA.

Applications due May 22, 2017

  Breast Cancer Alliance (BCA) (Deadline: 7/22/17)

Breast Cancer Alliance (BCA)

The mission of the Breast Cancer Alliance (BCA) is to improve survival rates and quality of life for those impacted by breast cancer through better prevention, early detection, treatment and cure. To promote these goals, the BCA invests in innovative research, breast surgery fellowships, regional education, dignified support and screening for the uninsured and underserved.

The BCA offers the Young Investigator Grant to encourage a commitment to breast cancer research. This grant is intended to help advance the careers of young researchers who do not yet have their own major grant support.

Applications due July 22, 2017

  Fanconi Anemia Research Fund (Deadline: 2/2/18)

Fanconi Anemia Research Fund

The Fund seeks to improve the lives of individuals with Fanconi anemia through research that focuses on the rapid discovery and development of therapies or strategies that treat, control or cure Fanconi anemia. It has a particular interest in funding interdisciplinary, translational research efforts that effectively address one or more of the following priorities:

  • To understand how alteration of the Fanconi anemia genes and their products lead to the clinical manifestations of Fanconi anemia.
  • To determine the causes of bone marrow failure, myelodysplasia and leukemia in individuals with Fanconi anemia, and to develop strategies to prevent, treat and cure these disorders.
  • To define the pathogenesis of cancers that affect persons with Fanconi anemia, and to develop strategies for early detection, prevention, treatment and cure.
  • To identify practical and proactive management strategies that families and persons with Fanconi anemia can use to develop and maintain a high quality of life.
  • To support the creation of shared resources, databases and technologies for the international Fanconi anemia research community.

Applications due February 02, 2018

  Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) (Deadline: Continuous)

Boehringer Ingelheim Pharma GmbH & Co. KG | Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI)

Medical Educational Grants are independent educational activities that utilize effective educational methods to address unmet medical needs that leads to improved patient outcomes. A Boehringer Ingelheim Pharmaceuticals, Inc. medical educational grant is designed to provide support for accredited educational programs for health care providers and non-accredited educational programs directed toward the patient and the local health care community.

The Medical Education Grants Department consists of education professionals who facilitate lifelong learning for clinicians and patients through support of independent education. BIPI's Medical Education and Research Grants department is committed to supporting innovative, high quality, independent medical education and research for healthcare professionals and patients that resolves unmet medical needs, fosters clinical excellence, and measurably improves health outcomes in areas of strategic focus to BIPI.

The sponsor considers funding of activities in many therapeutic areas including:

  • Therapeutic Areas Cardiovascular Disease – Stroke Prevention in Atrial Fibrillation
  • Cardiovascular Disease – Venous Thromboembolism (VTE)
  • Immunology – General Immunology
  • Oncology – Acute Myeloid Leukemia (AML)
  • Oncology – Lung Cancer
  • Respiratory Disease – Chronic Obstructive Pulmonary Disease (COPD)
  • Respiratory Disease – Interstitial Lung Disease (ILD)

Funding may be limited or exhausted in some therapeutic areas. BIPI will review and consider support of those requests in the areas above. To that end, educational objectives have been identified that are derived from evidence based science and are intended to close gaps in research, knowledge, or behaviors that represent barriers in care and patient outcomes.

Deadline continuous

  Sanofi-Aventis U.S. Inc. Education Grants (Deadline continuous)

Sanofi-Aventis U.S. Inc. Education Grants

Sanofi US is committed to funding high quality educational activities and materials in the therapeutic areas of interest to the company that have the potential to improve patient care and health outcomes.

The purpose of an educational grant is to support an activity that encourages an educational interchange with respect to available scientific and medical information. Educational activities may or may not be accredited.

Educational Grants fund educational activities and materials designed to improve the knowledge, competence (skill) and/or performance of healthcare professionals, patients, and/or consumers for improved patient care and outcomes.

Grants may be given for live educational activities, as well as educational publications and other types of enduring materials (e.g. interactive web, CD rom, audio tapes, etc.) provided that the activities or materials are advertised and open to a broad audience beyond members of the requesting institution. Fellowships or career development awards may be considered in limited circumstances.

Applicant must select one of the following Therapeutic Areas:

  • Cardiovascular
  • Diabetes
  • Genetic Diseases
  • Immunology
  • Multiple Sclerosis
  • Oncology
  • Orthopedics
  • Renal
  • Thyroid Cancer
  • Transplantation

Deadline continuous

Top